1. Market Research
  2. > Vaginitis – Pipeline Review, H1 2013

Vaginitis – Pipeline Review, H1 2013

  • May 2013
  • -
  • Global Markets Direct
  • -
  • 38 pages

Vaginitis – Pipeline Review, H1 2013

Summary

Global Markets Direct’s, 'Vaginitis - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Vaginitis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Vaginitis. Vaginitis - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Vaginitis.
- A review of the Vaginitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Vaginitis pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Vaginitis.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Vaginitis pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

Vaginitis - Pipeline Review, H1 2013
Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Vaginitis Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Vaginitis 7
Vaginitis Therapeutics under Development by Companies 9
Vaginitis Therapeutics under Investigation by Universities/Institutes 10
Late Stage Products 11
Comparative Analysis 11
Early Clinical Stage Products 12
Comparative Analysis 12
Discovery and Pre-Clinical Stage Products 13
Comparative Analysis 13
Vaginitis Therapeutics - Products under Development by Companies 14
Vaginitis Therapeutics - Products under Investigation by Universities/Institutes 15
Companies Involved in Vaginitis Therapeutics Development 16
Centaur Pharmaceuticals Pvt. Ltd. 16
BioDiem Ltd 17
NanoBio Corporation 18
Lee's Pharmaceutical Holdings Limited 19
Vaginitis - Therapeutics Assessment 20
Assessment by Monotherapy Products 20
Assessment by Combination Products 21
Assessment by Route of Administration 22
Assessment by Molecule Type 24
Drug Profiles 26
Drug For Vaginitis - Drug Profile 26
Product Description 26
Mechanism of Action 26
RandD Progress 26
(miconazole nitrate + neomycin sulphate + tinidazole) - Drug Profile 27
Product Description 27
Mechanism of Action 27
RandD Progress 27
BDM-I - Drug Profile 28
Product Description 28
Mechanism of Action 28
RandD Progress 28
ZK-004 - Drug Profile 29
Product Description 29
Mechanism of Action 29
RandD Progress 29
Drug For Candiasis - Drug Profile 30
Product Description 30
Mechanism of Action 30
RandD Progress 30
TOL-463 - Drug Profile 31
Product Description 31
Mechanism of Action 31
RandD Progress 31
Vaginitis Therapeutics - Drug Profile Updates 32
Vaginitis Therapeutics - Dormant Products 34
Vaginitis - Product Development Milestones 35
Featured News and Press Releases 35
Nov 21, 2012: BioDiem Files Japanese Patent Application For Antimicrobial Compound BDM-I 35
Aug 08, 2012: BioDiem Receives European Patent For Antimicrobial Compound BDM-I 36
Appendix 37
Methodology 37
Coverage 37
Secondary Research 37
Primary Research 37
Expert Panel Validation 37
Contact Us 38
Disclaimer 38



List of Tables

Number of Products Under Development for Vaginitis, H1 2013 7
Products under Development for Vaginitis - Comparative Analysis, H1 2013 8
Number of Products under Development by Companies, H1 2013 9
Number of Products under Investigation by Universities/Institutes, H1 2013 10
Comparative Analysis by Late Stage Development, H1 2013 11
Comparative Analysis by Early Clinical Stage Development, H1 2013 12
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2013 13
Products under Development by Companies, H1 2013 14
Products under Investigation by Universities/Institutes, H1 2013 15
Centaur Pharmaceuticals Pvt. Ltd., H1 2013 16
BioDiem Ltd, H1 2013 17
NanoBio Corporation, H1 2013 18
Lee's Pharmaceutical Holdings Limited, H1 2013 19
Assessment by Monotherapy Products, H1 2013 20
Assessment by Combination Products, H1 2013 21
Assessment by Stage and Route of Administration, H1 2013 23
Assessment by Stage and Molecule Type, H1 2013 25
Vaginitis Therapeutics - Drug Profile Updates 32
Vaginitis Therapeutics - Dormant Products 34



List of Figures

Number of Products under Development for Vaginitis, H1 2013 7
Products under Development for Vaginitis - Comparative Analysis, H1 2013 8
Products under Development by Companies, H1 2013 9
Products under Investigation by Universities/Institutes, H1 2013 10
Late Stage Products, H1 2013 11
Early Clinical Stage Products, H1 2013 12
Discovery and Pre-Clinical Stage Products, H1 2013 13
Assessment by Monotherapy Products, H1 2013 20
Assessment by Combination Products, H1 2013 21
Assessment by Route of Administration, H1 2013 22
Assessment by Stage and Route of Administration, H1 2013 23
Assessment by Molecule Type, H1 2013 24
Assessment by Stage and Molecule Type, H1 2013 25

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.